Clinical outcomes and genomic features of uncommon EGFR exon 19 deletion subtypes in osimertinib-treated non-small cell lung cancer

Study limitation reported by the research below: “Genomic co-alteration data (RBM10, CDKN2A/B, MYC) derive from public databases, not the primary clinical cohort, so direct causal links to outcomes cannot be established.”